Rhythm Pharma Presents Patient-Reported Experiences with Hyperphagia at ENDO 2024
Rhythm Pharmaceuticals, Inc. has presented the first patient and caregiver reported experiences from qualitative interviews following the completion of a Phase 2 trial.
Hypothalamic Obesity | 04/06/2024 | By Aishwarya | 173
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy